Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical stage immuno-oncology company, renowned for its innovation in next-generation cancer immunotherapies. Headquartered in Gaithersburg, MD, Sensei leverages its proprietary TMAb™ (Tumor Microenvironment Activated biologics) platform to develop cutting-edge therapeutics designed to harness the body's immune system against cancer. The company’s leading product candidates include SNS-101, SNS-102, SNS-103, and SNS-201, all of which are conditionally active antibodies targeting different immunosuppressive markers within the tumor microenvironment.
Sensei’s flagship candidate, SNS-101, is designed to block the VISTA (V-domain Ig suppressor of T cell activation) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 is currently undergoing a multi-center Phase 1/2 clinical trial, evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy as both a monotherapy and in combination with Regeneron's PD-1 inhibitor, Libtayo® (cemiplimab), in patients with advanced solid tumors. Initial data are promising, showing SNS-101 to be well-tolerated and demonstrating clinical activity, particularly in tumor types typically resistant to PD-1 monotherapy.
Other promising candidates include SNS-102, targeting VSIG-4 (V-Set and Immunoglobulin Domain Containing 4), and SNS-103, targeting CD39 (ecto-nucleoside triphosphate diphosphohydrolase-1), as well as SNS-201, a conditionally active VISTAxCD28 bispecific antibody. The company has established key academic collaborations, including with Brown University, to bolster its research and development efforts.
Financially, Sensei maintains a strong balance sheet with cash reserves projected to fund operations into the second half of 2025. Recent financial updates show reduced R&D and G&A expenses due to strategic restructuring, leading to a narrower net loss. The company is focused on advancing its clinical trials, with expected milestones including initial combination safety and pharmacokinetic data for SNS-101 in early 2024, followed by topline monotherapy data later in the year.
For more information, visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.
Sensei Biotherapeutics announced the FDA's clearance of its IND application for SNS-101, a VISTA-blocking antibody, enabling a Phase 1/2 clinical trial for patients with solid tumors. This key milestone is expected to significantly impact cancer treatment. The trial will assess SNS-101's safety, tolerability, pharmacokinetics, and efficacy, both alone and combined with Regeneron’s Libtayo® (cemiplimab). The initial patient dosing is anticipated in mid-2023. Preclinical data suggest SNS-101's promising potential to inhibit tumor growth and enhance PD-1 blockade effects, while maintaining better pharmacokinetics and reducing cytokine release syndrome risk.
Sensei Biotherapeutics (Nasdaq: SNSE) presented new preclinical data on its SNS-103 program at the AACR Annual Meeting 2023, focusing on targeting CD39, an enzyme linked to an immunosuppressive tumor microenvironment. The data suggests that SNS-103, a conditionally active monoclonal antibody, selectively binds to CD39 in low pH conditions typical of tumors, potentially improving anti-tumor immunity by preserving extracellular ATP and inhibiting adenosine generation.
The poster presentation highlighted the selection of 8 antibodies for further optimization from a panel of 83, with a lead product candidate expected to be selected in 2023. This advancement could position Sensei favorably within the immuno-oncology sector.
Sensei Biotherapeutics (Nasdaq: SNSE) announced its participation in a panel discussion titled ‘Overcoming Resistance & Immunosuppression in Solid Tumors’ at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, at 3:00 p.m. ET. The company specializes in developing next-generation therapeutics for cancer patients through its TMAb™ platform.
Sensei's lead candidate is SNS-101, designed to inhibit T cell suppression in the tumor microenvironment. The company is also advancing SNS-102, targeting VSIG-4, and SNS-103, which targets ENTPDase1, also known as CD39. For more information, visit www.senseibio.com.
BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics (Nasdaq: SNSE), an immuno-oncology firm, announced that its CEO, John Celebi, will participate in a panel on 'Novel Approaches in Immunotherapy' at the Cantor Fitzgerald's Future of Oncology Virtual Symposium on April 3rd at 10:00 a.m. ET.
Sensei Biotherapeutics focuses on developing next-generation therapeutics for cancer patients using its TMAb™ platform. The lead candidate is SNS-101, targeting VISTA in the tumor microenvironment. Other candidates include SNS-102 and SNS-103, which target VSIG-4 and ENTPDase1, respectively. For more details, visit www.senseibio.com.
Sensei Biotherapeutics (Nasdaq: SNSE) announced the submission of an Investigational New Drug (IND) application for its lead candidate, SNS-101, aimed at treating solid tumors through VISTA blockade. The company has formed partnerships with Regeneron, the National Cancer Institute, and Washington University to bolster development. Sensei expects to advance a second TMAb™ program to IND-enabling studies. The company reported a cash position of $107.1 million and projects a runway into the second half of 2025. However, the net loss increased to $48.6 million in 2022, up from $36.8 million in 2021.
Sensei Biotherapeutics (NASDAQ: SNSE) announced on March 21, 2023, the submission of an Investigational New Drug (IND) application to the FDA for SNS-101, a VISTA-blocking antibody targeting solid tumors. This therapy is designed to selectively inhibit the VISTA checkpoint, which suppresses T cell activity, potentially enhancing anti-tumor responses. Preclinical data indicate SNS-101's efficacy as a monotherapy and in combination with PD-1 blockade, while minimizing poor pharmacokinetics and cytokine release syndrome risks. Sensei aims to address solid cancers with this innovative therapeutic approach.
Sensei Biotherapeutics (NASDAQ: SNSE) will unveil new preclinical data on SNS-103, a monoclonal antibody targeting CD39, at the AACR Annual Meeting 2023 in Orlando from April 14-19, 2023. The presentation titled 'Identification of conditionally active antibodies that selectively block CD39 activity in the acidic tumor microenvironment' is scheduled for April 18, 2023, from 1:30 PM to 5:00 PM ET.
Sensei aims to develop therapeutics that activate immune responses against tumors utilizing its TMAb™ platform, and SNS-103 is part of its ongoing research in immune-oncology.
FAQ
What is the current stock price of Sensei Biotherapeutics (SNSE)?
What is the market cap of Sensei Biotherapeutics (SNSE)?
What is Sensei Biotherapeutics, Inc.?
What products is Sensei developing?
What is SNS-101?
What are the recent achievements of the company?
Where is Sensei Biotherapeutics headquartered?
What is the TMAb™ platform?
What financial status does Sensei Biotherapeutics have?
Who are Sensei's key collaborators?
What are the anticipated milestones for SNS-101?
Where can I find more information about Sensei Biotherapeutics?
